Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAA50 | Q9GZZ1 | 2/20 | 0.84 |
| ▸ | EP300 | Q09472 | 3/20 | 0.81 |
| ▸ | CHAT | P28329 | 2/20 | 0.81 |
| ▸ | AURKA | O14965 | 2/20 | 0.81 |
| ▸ | KAT5 | Q92993 | 2/20 | 0.81 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.81 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29512275 | 0.99 | NAA50 (0.83) | NAA50EP300CHATAURKAKAT5 | |
| SCHEMBL22715872 | 0.99 | NAA50 (0.83) | NAA50EP300CHATAURKAKAT5 | |
| SCHEMBL1333244 | 0.98 | NAA50 (0.84) | NAA50EP300CHATAURKAKAT5 | |
| SCHEMBL30558687 | 0.98 | NAA50 (0.84) | NAA50EP300CHATAURKAKAT5 | |
| SCHEMBL25273107 | 0.98 | NAA50 (0.83) | NAA50EP300CHATAURKAKAT5 | |
| SCHEMBL1332729 | 0.98 | NAA50 (0.83) | NAA50EP300CHATAURKAKAT5 | |
| SCHEMBL11026148 | 0.98 | NAA50 (0.83) | NAA50EP300CHATAURKAKAT5 | |
| SCHEMBL2510648 | 0.98 | NAA50 (0.83) | NAA50EP300CHATAURKAKAT5 | |
| SCHEMBL31475488 | 0.98 | NAA50 (0.83) | NAA50EP300CHATAURKAKAT5 | |
| SCHEMBL380634 | 0.98 | NAA50 (0.83) | NAA50EP300CHATAURKAKAT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9790525-B2 | Methods of producing 7-carbon chemicals via CoA-dependent carbon chain elongation associated with carbon storage | INVISTA NORTH AMERICA S.A.R.L. (US) | 2017-10-17 | — | — | US | claimed |
| US-20180002729-A1 | METHODS, REAGENTS AND CELLS FOR BIOSYNTHESIZING COMPOUNDS | INVISTA NORTH AMERICA S.A.R.L. | 2018-01-04 | — | — | US | disclosed |
| US-9790525-B2 | Methods of producing 7-carbon chemicals via CoA-dependent carbon chain elongation associated with carbon storage | INVISTA NORTH AMERICA S.A.R.L. (US) | 2017-10-17 | — | — | US | disclosed |
| US-9738914-B2 | Methods, reagents and cells for biosynthesizing compounds | INVISTA NORTH AMERICA S.A.R.L. (US) | 2017-08-22 | — | — | US | disclosed |
| EP-3155109-A1 | METHODS, REAGENTS AND CELLS FOR BIOSYNTHESIZING COMPOUNDS | Invista Technologies S.A R.L. (CH) | 2017-04-19 | — | — | EP | disclosed |
| WO-2015195678-A1 | METHODS, REAGENTS AND CELLS FOR BIOSYNTHESIZING COMPOUNDS | INVISTA TECHNOLOGIES S.À R.L. (CH) | 2015-12-23 | — | — | WO | disclosed |
| US-20150361465-A1 | METHODS, REAGENTS AND CELLS FOR BIOSYNTHESIZING COMPOUNDS | INV NYLON CHEMICALS AMERICAS, LLC | 2015-12-17 | — | — | US | disclosed |
| EP-2931907-A2 | METHODS OF PRODUCING 7-CARBON CHEMICALS VIA CoA-DEPENDENT CARBON CHAIN ELONGATION ASSOCIATED WITH CARBON STORAGE | Invista Technologies S.A R.L. (CH) | 2015-10-21 | — | — | EP | disclosed |
| US-20140248673-A1 | Methods of Producing 7-Carbon Chemicals via CoA-Dependent Carbon Chain Elongation Associated with Carbon Storage | INVISTA North America S.á r.I. (US) | 2014-09-04 | — | — | US | disclosed |
| WO-2014093847-A2 | METHODS OF PRODUCING 7-CARBON CHEMICALS VIA CoA-DEPENDENT CARBON CHAIN ELONGATION ASSOCIATED WITH CARBON STORAGE | INVISTA NORTH AMERICA S.A.R.L. (US) | 2014-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150361465-A1 | METHODS, REAGENTS AND CELLS FOR BIOSYNTHESIZING COMPOUNDS | PNMT, HNMT, ACOT7 | NAA50 212/4885EP300 886/4885CHAT 403/4885 |
| US-20180002729-A1 | METHODS, REAGENTS AND CELLS FOR BIOSYNTHESIZING COMPOUNDS | PNMT, HNMT, ACOT7 | NAA50 212/4885EP300 886/4885CHAT 403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.